Theilgaard-Mönch K - Search Results

1

TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event.

Reckzeh K, Estruch M, Ali M, Søgaard Helbo A, Mosbech A, Jae Won K, Rücker F, Döhner K, Theilgaard-Mönch K. Reckzeh K, et al. Br J Haematol. 2022 Apr;197(2):201-206. doi: 10.1111/bjh.18027. Epub 2022 Feb 6. Br J Haematol. 2022. PMID: 35128634 No abstract available.

2

Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin.

Reckzeh K, Kizilkaya H, Helbo AS, Alrich ME, Deslauriers AG, Grover A, Rapin N, Asmar F, Grønbæk K, Porse B, Borregaard N, Vestweber D, Nerlov C, Theilgaard-Mönch K. Reckzeh K, et al. Blood Adv. 2018 Jul 10;2(13):1628-1632. doi: 10.1182/bloodadvances.2018015743. Blood Adv. 2018. PMID: 29986855 Free PMC article.

3

Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.

Jakobsen JS, Laursen LG, Schuster MB, Pundhir S, Schoof E, Ge Y, d'Altri T, Vitting-Seerup K, Rapin N, Gentil C, Jendholm J, Theilgaard-Mönch K, Reckzeh K, Bullinger L, Döhner K, Hokland P, Fitzgibbon J, Porse BT. Jakobsen JS, et al. Sci Adv. 2019 Jul 10;5(7):eaaw4304. doi: 10.1126/sciadv.aaw4304. eCollection 2019 Jul. Sci Adv. 2019. PMID: 31309149 Free PMC article.

4

The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study.

Kristensen D, Nielsen LB, Roug AS, Kristensen TC, El-Galaly TC, Nørgaard JM, Marcher CW, Schöllkopf C, Theilgaard-Mönch K, Severinsen MT. Kristensen D, et al. Br J Haematol. 2020 Jul;190(2):236-243. doi: 10.1111/bjh.16667. Epub 2020 Apr 21. Br J Haematol. 2020. PMID: 32316076 Free PMC article.

5

Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study.

Hjort Jakobsen L, Stidsholt Roug A, Kiesbye Øvlisen A, Werenberg Marcher C, Beier Ommen H, Theilgaard-Mönch K, Møller P, Schöllkopf C, Kristensen D, Maria Henriette Naur T, Bøgsted M, Christoffer El-Galaly T, Tang Severinsen M. Hjort Jakobsen L, et al. Br J Haematol. 2021 May;193(3):482-487. doi: 10.1111/bjh.17213. Epub 2020 Nov 21. Br J Haematol. 2021. PMID: 33222154 Free article.

6

Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy.

Estruch M, Reckzeh K, Vittori C, Centio A, Ali M, Engelhard S, Zhao L, Won KJ, Liu P, Porse BT, Theilgaard-Mönch K. Estruch M, et al. Leukemia. 2021 Jul;35(7):2030-2042. doi: 10.1038/s41375-020-01094-0. Epub 2020 Dec 9. Leukemia. 2021. PMID: 33299144

7

MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.

Sanjiv K, Calderón-Montaño JM, Pham TM, Erkers T, Tsuber V, Almlöf I, Höglund A, Heshmati Y, Seashore-Ludlow B, Nagesh Danda A, Gad H, Wiita E, Göktürk C, Rasti A, Friedrich S, Centio A, Estruch M, Våtsveen TK, Struyf N, Visnes T, Scobie M, Koolmeister T, Henriksson M, Wallner O, Sandvall T, Lehmann S, Theilgaard-Mönch K, Garnett MJ, Östling P, Walfridsson J, Helleday T, Warpman Berglund U. Sanjiv K, et al. Cancer Res. 2021 Nov 15;81(22):5733-5744. doi: 10.1158/0008-5472.CAN-21-0061. Epub 2021 Sep 30. Cancer Res. 2021. PMID: 34593524 Free PMC article.

8

Inhibition of Oxidized Nucleotide Sanitation By TH1579 and Conventional Chemotherapy Cooperatively Enhance Oxidative DNA Damage and Survival in AML.

Centio A, Estruch M, Reckzeh K, Sanjiv K, Vittori C, Engelhard S, Warpman Berglund U, Helleday T, Theilgaard-Mönch K. Centio A, et al. Mol Cancer Ther. 2022 May 4;21(5):703-714. doi: 10.1158/1535-7163.MCT-21-0185. Mol Cancer Ther. 2022. PMID: 35247918

9

Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.

Pfeiffer A, Franciosa G, Locard-Paulet M, Piga I, Reckzeh K, Vemulapalli V, Blacklow SC, Theilgaard-Mönch K, Jensen LJ, Olsen JV. Pfeiffer A, et al. Among authors: theilgaard monch k. Cancer Res. 2022 Jun 6;82(11):2141-2155. doi: 10.1158/0008-5472.CAN-21-0548. Cancer Res. 2022. PMID: 35311954 Free PMC article.

10

Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance.

Estruch M, Vittori C, Montesinos TM, Reckzeh K, Theilgaard-Mönch K. Estruch M, et al. Among authors: theilgaard monch k. Cancer Drug Resist. 2021 Nov 10;4(4):984-995. doi: 10.20517/cdr.2021.76. eCollection 2021. Cancer Drug Resist. 2021. PMID: 35582388 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters